Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.

Q1 Medicine

CNS Oncology Pub Date : 2021-09-01 Epub Date: 2021-09-06 DOI:10.2217/cns-2021-0002

Ngan Nguyen, Jordan Redfield, Matthew Ballo, Madison Michael, Jeffrey Sorenson, Daniel Dibaba, Jim Wan, Glenda Delgado Ramos, Manjari Pandey

{"title":"Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.","authors":"Ngan Nguyen, Jordan Redfield, Matthew Ballo, Madison Michael, Jeffrey Sorenson, Daniel Dibaba, Jim Wan, Glenda Delgado Ramos, Manjari Pandey","doi":"10.2217/cns-2021-0002","DOIUrl":null,"url":null,"abstract":"Aim: To define the optimal cutoff point for determining methylation status of O6-methylguanine-DNA methyltransferase (MGMT) by pyrosequencing in glioblastoma. Patients & methods: A retrospective study of 109 glioblastoma patients was performed to determine the optimal cutoff point for MGMT methylation status. Results: Receiver operating characteristic (ROC) analysis revealed 21% as the optimal cutoff (sensitivity: 68%; specificity: 59%) for MGMT methylation corresponding with the highest likelihood ratio of 1.66 and accuracy of 0.65. Methylation status (hazard ratio: 0.453; 95% CI: 0.279-0.735; p = 0.001) was associated with better overall survival. The crude model indicated linearity between methylation percent and survival rate; an increase of 10% of methylation resulted in a reduction of risk of death by 20% (p = 0.004). Conclusion: ROC analysis determined 21% as the optimal cutoff point for MGMT methylation status by pyrosequencing.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/0e/cns-10-74.PMC8461752.pdf","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2021-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 9

Abstract

Aim: To define the optimal cutoff point for determining methylation status of O6-methylguanine-DNA methyltransferase (MGMT) by pyrosequencing in glioblastoma. Patients & methods: A retrospective study of 109 glioblastoma patients was performed to determine the optimal cutoff point for MGMT methylation status. Results: Receiver operating characteristic (ROC) analysis revealed 21% as the optimal cutoff (sensitivity: 68%; specificity: 59%) for MGMT methylation corresponding with the highest likelihood ratio of 1.66 and accuracy of 0.65. Methylation status (hazard ratio: 0.453; 95% CI: 0.279-0.735; p = 0.001) was associated with better overall survival. The crude model indicated linearity between methylation percent and survival rate; an increase of 10% of methylation resulted in a reduction of risk of death by 20% (p = 0.004). Conclusion: ROC analysis determined 21% as the optimal cutoff point for MGMT methylation status by pyrosequencing.

Abstract Image

查看原文本刊更多论文

确定胶质母细胞瘤中MGMT启动子甲基化状态的最佳截止点。

目的:确定用焦磷酸测序法测定胶质母细胞瘤中o6 -甲基鸟嘌呤- dna甲基转移酶(MGMT)甲基化状态的最佳截止点。患者和方法:对109例胶质母细胞瘤患者进行回顾性研究，以确定MGMT甲基化状态的最佳截止点。结果:受试者工作特征(ROC)分析显示21%为最佳截止值(灵敏度:68%;特异性:59%)MGMT甲基化的最高似然比为1.66，准确率为0.65。甲基化状态(风险比:0.453;95% ci: 0.279-0.735;P = 0.001)与较好的总生存率相关。粗模型显示甲基化率与存活率呈线性关系;甲基化增加10%导致死亡风险降低20% (p = 0.004)。结论:ROC分析通过焦磷酸测序确定21%为MGMT甲基化状态的最佳截止点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS Oncology Medicine-Neurology (clinical)

CiteScore

3.80

自引率

0.00%

发文量

审稿时长

13 weeks